FOR IMMEDIATE RELEASE
Washington, D.C. | March 13, 2025
HyperVigilant Inc., an innovative AI-driven health technology company, has officially launched with a bold mission: to transform how hypertension is predicted, diagnosed, and managed—particularly in underserved communities that have long faced systemic neglect and unequal care.
Founded by Dr. Maya Rockeymoore Cummings, a respected policy leader, strategist, and advocate for health equity, HyperVigilant is as much a personal journey as it is a professional endeavor. Dr. Rockeymoore Cummings was inspired to create the platform following the heartbreaking loss of her husband, Congressman Elijah Cummings, who suffered for years from undertreated hypertension. Misdiagnosed, mistreated, and prescribed the wrong medications, Elijah’s condition went unmanaged until it was too late. His story, sadly, is one of many.
“Elijah’s passing exposed the deep gaps in how our health system approaches chronic disease care, especially for people of color,” said Dr. Rockeymoore Cummings. “HyperVigilant was born out of love, urgency, and the realization that no one should suffer needlessly from a largely preventable and highly manageable condition.”
HyperVigilant harnesses artificial intelligence to close these gaps by:
- Predicting risk early using EHRs, wearable data, and social determinants of health.
- Diagnosing with precision by integrating clinical trends and personalized factors.
- Managing care holistically through culturally responsive treatment plans, remote monitoring, and virtual support tools.
HyperVigilant is already gaining traction. It has been accepted into Microsoft’s Hub for Startups and is building its model using Azure and OpenAI technologies. With partnerships forming across the country, including interest from public health systems and hospitals, the company is preparing to launch a pilot program alongside the development of its minimum viable product (MVP).
“Our AI model is designed with the communities most impacted by hypertension in mind—Black, Brown, rural, and low-income populations,” said Rockeymoore Cummings. “We want to empower patients and providers alike with the tools to take control of their health.”
With the support of a prestigious advisory board and a growing base of allies in public health, technology, and philanthropy, HyperVigilant is poised to lead a new era of equity-focused, AI-enabled care.
About HyperVigilant
HyperVigilant Inc. is a health technology company focused on improving hypertension detection, diagnosis, and management through artificial intelligence. The platform integrates clinical, behavioral, and social data to provide personalized, culturally competent care. HyperVigilant is committed to reducing disparities and improving population health outcomes in the communities that need it most.
Learn more at www.HyperVigilant.com.
